CN Patent

CN1867564B — 氨基巴豆基化合物的制备方法

Assigned to Boehringer Ingelheim International GmbH · Expires 2011-06-08 · 15y expired

What this patent protects

本发明是关于一种用于制备4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N，N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-((S)-四氢呋喃-3-基氧)-喹唑啉以及相关的氨基巴豆基化合物的改良方法，以及用作医药活性物质的4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N，N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-((S)-四氢呋喃-3-基氧)-喹唑啉的适宜的盐的制备。

USPTO Abstract

本发明是关于一种用于制备4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N，N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-((S)-四氢呋喃-3-基氧)-喹唑啉以及相关的氨基巴豆基化合物的改良方法，以及用作医药活性物质的4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N，N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-((S)-四氢呋喃-3-基氧)-喹唑啉的适宜的盐的制备。

Drugs covered by this patent

afatinib-dimaleate (AFATINIB DIMALEATE)

Patent Metadata

Patent number: CN1867564B
Jurisdiction: CN
Classification: —
Expires: 2011-06-08
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.